Disease: Carcinoma breast stage IV ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE PI3K/mTOR/CDK4/6 inhibitors may influence the development of edema, which may cause or exacerbate progression of BCRL in patients with MBC. 30919166 2019
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Collectively, these findings suggest that while <i>FGFR1</i> amplification confers broad resistance to ER, PI3K, and CDK4/6 inhibitors, mTOR inhibitors might have a unique therapeutic role in the treatment of patients with ER<sup>+</sup>/FGFR1<sup>+</sup> MBC. 31371343 2019
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 GeneticVariation disease BEFREE A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. 29153866 2018
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 GeneticVariation disease BEFREE Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. 29103666 2017
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Our data suggest that additional PI3K blockade might be effective in enhancing the therapeutic effect of tamoxifen in ER-positive BC and support the rationale combination in clinical trials. 28852212 2017
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Metastatic breast cancer (MBC) progressing after endocrine therapy frequently activates PI3K/AKT/mTOR pathway. 28727815 2017
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study. 27573562 2016
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE MYC gene copies, centromere status and PI3K activation may adversely impact trastuzumab treated mBC patient outcome and seem worthy validating in larger series. 27184134 2016
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. 26497877 2015
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Here, resistance to a class I PI3K inhibitor in a model of metastatic breast cancer driven by PI3K and MYC was associated with feedback activation of tyrosine kinase receptors (RTKs), AKT, mTOR, and MYC. 26058079 2015
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 Biomarker disease BEFREE Amplified PI3K/Akt/mTOR signaling is common in metastatic breast cancer (MBC). 26456573 2015
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 GeneticVariation disease BEFREE The purpose of this study was to determine the clinical activity of the PI3K inhibitor buparlisib (BKM120) in patients with HER2(+) advanced/metastatic breast cancer resistant to trastuzumab-based therapy. 24470511 2014
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 AlteredExpression disease BEFREE Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies. 24595002 2014
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 AlteredExpression disease BEFREE PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. 21490305 2011
CUI: C0278488
Disease: Carcinoma breast stage IV
Carcinoma breast stage IV 		0.100 AlteredExpression disease BEFREE Here, we used low-density arrays, quantitative PCR, and western blotting to determine how HER2 signaling inhibition with lapatinib or PI3K inhibitors affects the expression of genes involved in breast cancer metastatic spread and overall prognosis. 20126311 2010